Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow EPRX by emailGet an email when EPRX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about EPRX, unsubscribe in one click. Privacy
📣 What EPRX Says Is Next
Q4 2026 · “The interim data from the Phase 2b part of the RESOLVE trial is expected in Q4 2026.”
Company press release, Aug 13, 2026 · SEC filing
coming months · “Eupraxia plans to disclose additional data from the open-label Phase 1b/2a part of the RESOLVE trial in the coming months.”
Company press release, Aug 13, 2026 · SEC filing
Q4 · “We continue to anticipate our key Phase 2b placebo-controlled interim readout in Q4 of this year.” Key results from the analysis of odynophagia following dosing with EP-104GI Patients in the RESOLVE trial were asked to grade the degree of odynophagia (pain whilst swallowing) on an 11-point scale (0 = no pain, 10 = most severe pain) over the seven previous days.”
Company press release, Aug 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full EPRX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EPRX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.